Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
A phase 2 trial of Abarelix in Prostate cancer, run by PRAECIS Pharmaceuticals Inc., completed.
Overview
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy is a phase 2 interventional study registered as NCT00100243 by PRAECIS Pharmaceuticals Inc., with 22 participants recorded, started 2004-05. Interventions recorded: Plenaxis. Conditions recorded: Prostate Cancer.
Linked to the drug Abarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialAbarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Shares Abarelix, Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialEvaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Shares Prostate cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Prostate cancer and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialFirst-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Shares Prostate cancer and the tag pipeline.